Signos offers an FDA-cleared, over-the-counter continuous glucose monitoring (CGM) system combined with an AI engine that scores meals and activities based on each user's glucose responses. The platform provides personalized feedback to help users understand which foods and behaviors drive glucose changes and to track trends toward weight-management goals. Signos positions its offering as complementary to GLP-1 medications by providing metabolic self-knowledge that supports long-term results. The company has grown tenfold over the past six months and is expanding distribution through a partnership with Dexcom, which will make Signos available on Stelo.com. Signos was founded in 2018 with a stated mission to eliminate obesity, and its product requires no prescription. The recent $20 million raise is intended to accelerate the company's growth and broaden access to its system.

Total raised

$53M

Funding rounds

3

Latest round

Equity

Latest activity

May 2026